Holen Sie sich die Stockscreener-App
32.85
2.95%
-1.00
Ideaya Biosciences Inc Aktie (IDYA) Neueste Nachrichten
Form 4 Ideaya Biosciences Inc For: 8 October By Investing.com - Investing.com Nigeria
Idea Biosciences president and CEO Yujiro Hata sells $985k in shares - Investing.com
Form 4 Ideaya Biosciences Inc For: 8 October By Investing.com - Investing.com UK
Option exercises are part of a CEO's proposed share sale at IDEAYA (Nasdaq: IDYA). - Stock Titan
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development - Yahoo Finance
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Santa Maria Times
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - TradingView
IDEAYA Biosciences (Nasdaq:IDYA)Stock Analysis - Simply Wall Street
IDEAYA at citigroup’s biopharma back to school summit 2026: pipeline breadth - Investing.com Canada
IDYA: NDA submission, ESMO data, and Roche collaborations set the stage for major oncology advances - TradingView
IDEAYA Biosciences at Cantor Fitzgerald conference: launch and pipeline push - Investing.com
IDEAYA Biosciences at Cantor Fitzgerald conference: launch and pipeline push - Investing.com Canada
IDEAYA Biosciences at Cantor Fitzgerald conference: launch and pipeline push - Investing.com India
IDEAYA Biosciences Doses First Patient in Phase 3 Trial - grafa.com
Guggenheim raises Ideaya Biosciences stock price target on DLL3 data - Investing.com
Guggenheim raises Ideaya Biosciences stock price target on DLL3 data By Investing.com - Investing.com Canada
IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma - PR Newswire
IDEAYA at wells fargo healthcare conference: darovasertib nears NDA By Investing.com - Investing.com Nigeria
IDEAYA at wells fargo healthcare conference: darovasertib nears NDA By Investing.com - Investing.com Canada
IDEAYA at wells fargo healthcare conference: darovasertib nears NDA By Investing.com - Investing.com India
Phase III path opens for Ideaya’s IDE-849 in DLL3 ADC horse race - BioWorld News
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA) - theglobeandmail.com
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Citizens upgrades Ideaya Biosciences stock rating on IDE849 progress By Investing.com - Investing.com Nigeria
IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences - 富途牛牛
Citizens upgrades Ideaya Biosciences stock rating on IDE849 progress - Investing.com
IDEAYA Biosciences Sets London R&D Day for Nov. 16 | IDYA Stock News - Stock Titan
Citizens upgrades Ideaya Biosciences stock rating on IDE849 progress By Investing.com - Investing.com Canada
Avoiding Lag: Real-Time Signals in (IDYA) Movement - Stock Traders Daily
IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer - PR Newswire
IDEAYA Biosciences Announces Successful FDA Type C Meeting For IDE849 DLL3 TOP1 ADC On Phase 3 Registrational Trial Design For Potential Accelerated And Full Approval In Extensive Stage Small Cell Lung Cancer - marketscreener.com
IDEAYA Biosciences (IDYA) Slips 2.3% to $40.81 as Biotech Momentum FadesMomentum Factor - vinanet.vn
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Ideaya Biosciences stock hits 52-week high at 40.88 USD By Investing.com - Investing.com Nigeria
Ideaya Biosciences stock hits 52-week high at 40.88 USD By Investing.com - Investing.com Australia
Ideaya Biosciences stock hits 52-week high at 40.88 USD - Investing.com
Ideaya Biosciences stock hits 52-week high at 40.88 USD By Investing.com - Investing.com Canada
Ideaya Biosciences stock hits 52-week high at 40.88 USD By Investing.com - Investing.com UK
Ideaya Biosciences: Darovasertib De-Risks A Self-Reinforcing Oncology Platform (IDYA) - Seeking Alpha
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Eastern Progress
IDEAYA (IDYA) Close: Adds 1.43% to Close at $39.67 at the Close; Technical Setup: the Near-Term Reference Band Stretches From $37.69 to $41.65 in the Available RecordFloat Adjusted Cap - vinanet.vn
Great Lakes Advisors LLC Makes New Investment in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA (IDYA) Results Check: The EPS Result Is Below Expectation in Latest Trading; Shares Close 2.48% Higher for the Current SessionEarnings Miss Alert - Vinanet
symbol__ Stock Quote Price and Forecast - CNN
IDEAYA partners with Genentech on pancreatic cancer trial By Investing.com - Investing.com South Africa
IDEAYA partners with Genentech on pancreatic cancer trial By Investing.com - Investing.com Nigeria
IDEAYA partners with Genentech on pancreatic cancer trial By Investing.com - Investing.com Canada
IDEAYA partners with Genentech on pancreatic cancer trial - Investing.com
4.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):